Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Plasma metabolomic profiling of individuals with autism spectrum disorder and their family members.

ABSTRACT: Autism spectrum disorder (ASD) is a common neurodevelopmental condition affecting 2.3% of 8-year-old children and is attributable to polygenic risks in most cases. Gene discovery studies catalogued >1000 genes with de novo, rare and common genetic variants that are likely associated with ASD; however, the candidate genes are rarely translated to diagnostic and treatment biomarkers. As such no pharmacological treatment option is available for targeting core symptoms. Neural circuits involved in verbal/nonverbal communications and social interaction are likely changed, which may be caused by an excitatory-inhibitory (E-I) imbalance in individuals with ASD. To date, clinical trials targeting excitatory glutamatergic or inhibitory GABAergic receptors showed mixed results. These early clinical trials highlight the unmet need of biomarkers for target populations and outcome indicators. We investigated whether plasma biomarkers would be associated with genetic risk factors and core symptoms of ASD. Plasma samples were collected for metabolomics profiling from the Autism Genetics Resource Exchange (AGRE). Detailed phenotype information is available at NIMH Data Archive (Collection ID: 4214) and can be accessed using NDAR GUID for the individuals.

ORGANISM(S): Human Homo Sapiens

TISSUE(S): Blood

DISEASE(S): Autism

SUBMITTER: Sek Won Kong

PROVIDER: ST002332 | MetabolomicsWorkbench | Fri Oct 14 00:00:00 BST 2022

REPOSITORIES: MetabolomicsWorkbench

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	mwtab	Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcription profiling of human peripheral blood mononuclear cells treated with a CDK inhibitor

Project description:A genomics-based approach to identify pharmacodynamic biomarkers was used for a CDK (cyclin-dependent kinase) inhibitory drug. R547 is a potent CDK inhibitor with a potent anti-proliferative effect at pharmacologically relevant doses, and is currently in Phase I clinical trials. Utilizing preclinical data derived from microarray experiments, we identified pharmacodynamic biomarkers to test in blood samples from patients in clinical trials. These candidate biomarkers were chosen based on several criteria: relevance to the mechanism of action of R547, dose responsiveness in preclinical models, and measurable expression in blood samples. We identified 26 potential biomarkers of R547 action and tested their clinical validity in patient blood samples by quantitative real-time PCR analysis. Experiment Overall Design: 40 samples were initially run, 37 passed QC and were analyzed, samples were run in 6 independent replicates and were treated with either vehicle, R547 at the IC90, or R547 at 3 times the IC90. Additionally, untreated time zero samples were analyzed as a further control

2009-03-28 | E-GEOD-15389 | biostudies-arrayexpress

Transcriptome analysis of Shank2 mutant mice

Project description:Autism spectrum disorders (ASDs) are a group of developmental disorders that cause variable and heterogeneous phenotypes across three behavioral domains such as atypical social behavior, disrupted communications, and highly restricted and repetitive behaviors. In addition to these core symptoms, other neurological abnormalities are associated with ASD, including intellectual disability (ID). However, the molecular etiology underlying these behavioral heterogeneities in ASD is unclear. Mutations in SHANK2 genes are associated with ASD and ID. Interestingly, two lines of Shank2 knockout mice (e6-7 KO and e7 KO) showed shared and distinct phenotypes. Here, we found that the expression levels of Gabra2, as well as of GABA receptor-mediated inhibitory neurotransmission, are reduced in Shank2 e6-7, but not in e7 KO mice compared with their own wild type littermates. Furthermore, treatment of Shank2 e6-7 KO mice with an allosteric modulator for the GABAA receptor reverses spatial memory deficits, indicating that reduced inhibitory neurotransmission may cause memory deficits in Shank2 e6-7 KO mice. This article is part of the Special Issue entitled 'Ionotropic glutamate receptors'.

2017-01-24 | GSE79824 | GEO

HCT116 tumor cells treated with a CDK inhibitor

2009-03-26 | GSE15395 | GEO

DU145 tumor cells treated with a CDK inhibitor

2009-03-26 | GSE15392 | GEO

Peripheral blood mononuclear cells treated with a CDK inhibitor

2009-03-26 | GSE15389 | GEO

Transcription profiling of human DU145 tumor cells treated with a CDK inhibitor (Super Series)

Project description:A genomics-based approach to identify pharmacodynamic biomarkers was used for a CDK (cyclin-dependent kinase) inhibitory drug. R547 is a potent CDK inhibitor with a potent anti-proliferative effect at pharmacologically relevant doses, and is currently in Phase I clinical trials. Utilizing preclinical data derived from microarray experiments, we identified pharmacodynamic biomarkers to test in blood samples from patients in clinical trials. These candidate biomarkers were chosen based on several criteria: relevance to the mechanism of action of R547, dose responsiveness in preclinical models, and measurable expression in blood samples. We identified 26 potential biomarkers of R547 action and tested their clinical validity in patient blood samples by quantitative real-time PCR analysis. Experiment Overall Design: 52 samples were initially run, 45 passed QC and were analyzed, samples were run in 4 independent replicates and were treated with either vehicle, R547 at the IC50 concentration, R547 at the IC90, or R547 at 3 times the IC90. Samples were harvested at 2, 6, and 24 hours post treatment. Additionally, untreated time zero samples were analyzed as a further control

2009-03-28 | E-GEOD-15392 | biostudies-arrayexpress

Transcription profiling of human HCT116 tumor cells treated with R547 a CDK inhibitor at IC50 concentration, R547 at the IC90, or R547 at 3 times the IC90m, time series design

Project description:A genomics-based approach to identify pharmacodynamic biomarkers was used for a CDK (cyclin-dependent kinase) inhibitory drug. R547 is a potent CDK inhibitor with a potent anti-proliferative effect at pharmacologically relevant doses, and is currently in Phase I clinical trials. Utilizing preclinical data derived from microarray experiments, we identified pharmacodynamic biomarkers to test in blood samples from patients in clinical trials. These candidate biomarkers were chosen based on several criteria: relevance to the mechanism of action of R547, dose responsiveness in preclinical models, and measurable expression in blood samples. We identified 26 potential biomarkers of R547 action and tested their clinical validity in patient blood samples by quantitative real-time PCR analysis. Experiment Overall Design: 77 samples were initially run, 74 passed QC and were analyzed, samples were run in 4 independent replicates and were treated with either vehicle, R547 at the IC50 concentration, R547 at the IC90, or R547 at 3 times the IC90. Samples were harvested at 1, 2, 4, 6, and 24 hours post treatment. Additionally, untreated time zero samples were analyzed as a further control

2009-03-28 | E-GEOD-15395 | biostudies-arrayexpress

Prefrontal D2- dopamine receptor deactivates top-down inhibitory control by regulating striatal cholinergic interneurons

Project description:Inhibitory control is a core cognitive function preventing the expression of maladaptive behaviors. This function is overridden in mental illnesses including bipolar disorder, autism spectrum disorders and schizophrenia, causing maladaptive psychomotor agitation. We developed intersectional CRISPR/Cas9 targeting approaches in adult mice to identify receptor/circuit selective mechanisms responsible for inactivation of inhibitory control in two models of amphetamine-induced psychomotor agitation. Inactivation of dopamine D2-receptors in the medial-prefrontal cortex (mPFC) abolished amphetamine-induced: psychomotor agitation, motor sensitization, and cAMP-associated transcriptome changes in the striatum. Further characterization using intersectional projection preparations indicate that these deficits implicate D2-receptors expressed on projection neurons innervating cholinergic interneurons of the dorsomedial striatum (DMS). Trans-synaptic targeting of acetylcholine production in DMS neurons receiving these projections restored psychomotor agitation in mice lacking mPFC D2- receptor expression. These findings identify a circuit by which activation of cortical D2-receptor circumvent an acetylcholine-mediated inhibition of DMS functions by the mPFC to promote psychomotor activation.

2023-06-17 | GSE234994 | GEO

Proteomics identifies potential biomarkers and implicates the granin family in Parkinson’s disease

Project description:Parkinson’s disease (PD) is the second most common neurodegenerative disorder. Treatments are available to address PD motor symptoms, but not disease progression or cognitive decline. Demonstrating disease modification in clinical trials is still a substantial challenge because of the high disease heterogeneity and variability in progression as well as subjectivity in clinical scoring. To develop novel therapeutics for PD, there is an urgent need to identify biomarkers for patient stratification in clinical trials. In this study, we used cutting edge data-independent acquisition (DIA) mass spectrometry to identify PD-specific biomarkers in patient cerebrospinal fluid (CSF). To identify novel biomarkers with minimal false discovery, two independent cohorts were analyzed by DIA mass spectrometry. An initial discovery cohort of 53 PD and 72 control (CTRL) patient samples was analyzed, identifying 53 proteins with significant changes (nominal p-value ≤ 0.05) in PD relative to CTRL out of the 342 detectable proteins. A second cohort of 28 PD and 43 CTRL samples were analyzed as above and identified 41 proteins with significant changes in PD. Thirteen proteins showed significant changes in both cohorts, some of which are previously reported to be altered in PD (i.e., EPHA4 and SERPINC1). Three members of a specific protein family, which are cleaved into bioactive peptides, were amongst these 13 proteins . Further, peptide-level quantification of the detectable members of this protein family (7 total) revealed that specific regions of all 7 proteins are decreased in Parkinson’s disease samples. Together, these data may implicate altered processing, localization, and/or function of this entire protein family for the first time in PD.

2020-02-19 | PXD011216 | Pride

Top2a promotes the development of social behavior via PRC2 and H3K27me3

Project description:Human infants exhibit innate social behaviors at birth, yet little is understood about the embryonic development of sociality. We screened 1120 known drugs and found that embryonic inhibition of topoisomerase IIα (Top2a) resulted in lasting social deficits in zebrafish. In mice, prenatal Top2 inhibition caused behavioral defects related to core symptoms of autism, including impairments in social interaction and communication. Mutation of Top2a in zebrafish caused downregulation of a set of genes highly enriched for genes associated with autism in humans. Both the Top2a-regulated and autism-associated gene sets possess binding sites for polycomb repressive complex 2 (PRC2), a regulatory complex responsible for H3K27 trimethylation. Moreover, both gene sets are highly enriched for H3K27me3. Inhibition of PRC2 component Ezh2 rescued social deficits caused by Top2 inhibition. Therefore, Top2a is a key component of an evolutionarily conserved pathway that promotes the development of social behavior through PRC2 and H3K27me3.

2021-09-20 | GSE181730 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data